ArticleWorld journal of gastrointestinal oncology2017
Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers.
Article in World journal of gastrointestinal oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Effect of concomitant chemotherapy on edoxaban plasma concentration in patients with colorectal cancer.BMC gastroenterology · 2026Article
- Development and validation of a machine learning model for predicting venous thromboembolism complications following colorectal cancer surgery.Visual computing for industry, biomedicine, and art · 2025Article
- Venous Thromboembolic Events Following Revisional Gastric Bypass: An Analysis of the MBSAQIP Database from 2015 to 2019 Using Propensity Matching.Obesity surgery · 2024Article
- A nomogram to predict the risk of venous thromboembolism in patients with colon cancer in China.Cancer medicine · 2024Article
- The Role of KRAS Mutation in Colorectal Cancer-Associated Thrombosis.International journal of molecular sciences · 2023Article
- Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer-VTE Registry).Cancer science · 2022Article
- Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Article
- Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan.Crohn's & colitis 360 · 2021Article
- MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2020Article
- Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: aTherapeutic advances in medical oncology · 2020Article
- Cancer-associated thrombosis: The search for the holy grail continues.Research and practice in thrombosis and haemostasis · 2018Review
- Thrombosis in cancer patients: etiology, incidence, and management.Cardiovascular diagnosis and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterise venous thromboembolism (VTE) in gastrointestinal cancer and assess the clinical utility of risk stratification scoring.
methodsWe performed a retrospective analysis using electronic patient records of 910 gastro-oesophageal (GO) cancer and 1299 colorectal cancer (CRC) patients referred to a tertiary cancer centre to identify the incidence of VTE, its relationship to chemotherapy and impact on survival. VTE risk scores were calculated using the Khorana index. Patients were classified as low risk (0 points), intermediate risk (1 to 2 points) or high risk (3 points). Data was analysed to determine the sensitivity of the Khorana score to predict VTE.
resultsThe incidence of VTE was 8.9% for CRC patients and 9.7% for GO cancer patients. Pulmonary emboli (PE) were more common in advanced than in localised CRC (50%
conclusionThe Khorana score has low sensitivity for thrombotic events in CRC and cannot discriminate low risk patients in high risk cancer sites such as GO cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.